Opportunistic autoimmune disorders: From immunotherapy to immune dysregulation

Yi Chi M. Kong, Wei Zen Wei, Yaron Tomer

Research output: Chapter in Book/Report/Conference proceedingChapter

23 Scopus citations


Rapid advances in our understanding of the immune network have led to treatment modalities for malignancies and autoimmune diseases based on modulation of the immune response. Yet therapeutic modulation has resulted in immune dysregulation and opportunistic autoimmune sequelae, despite prescreening efforts in clinical trials. This review focuses on recent clinical data on opportunistic autoimmune disorders arising from three immunotherapeutic modalities: (1) systemic immunomodulators, including interferon-α (also used to treat hepatitis C patients) and interferon-β; (2) monoclonal antibodies to CTLA-4 and CD52, and (3) hematopoietic stem cell transplantation. Uncategorized predisposing factors in these patients include major histocompatibility complex and gender genetics, prevalence of different autoimmune diseases, prior chemotherapy, underlying disorder (e.g., hepatitis C), and preconditioning regimens as part of organ and stem cell transplants. Not unexpectedly, the prevalent autoimmune thyroid disease surfaced frequently. Our combination models to study the balance between thyroid autoimmunity and tumor immunity upon regulatory T-cell perturbation are briefly described.

Original languageEnglish (US)
Title of host publicationThe Year in Immunology 2
PublisherBlackwell Publishing Inc.
Number of pages15
ISBN (Print)9781573317795
StatePublished - Jan 10 2010
Externally publishedYes

Publication series

NameAnnals of the New York Academy of Sciences
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632


  • Autoimmunity
  • Immune dysregulation
  • Immunotherapeutic sequelae
  • Immunotherapy
  • Opportunistic autoimmunity

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science


Dive into the research topics of 'Opportunistic autoimmune disorders: From immunotherapy to immune dysregulation'. Together they form a unique fingerprint.

Cite this